Stem Cell Transplantation Safe For Elderly Patients
ARLINGTON HEIGHTS, Ill., Feb. 19, 2013 /PRNewswire-USNewswire/ -- Researchers have shown that stem cell transplantation for elderly patients with blood cancers, such as leukemia, lymphoma or myelodysplastic syndrome (MDS), is safe and effective, according to research presented last week in Salt Lake City at the 2013 BMT Tandem Meetings, the combined annual meetings of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research.
Prior to this study, little was known about the safety of stem cell transplants in patients over the age of 70, who may have previously been excluded as candidates for stem cell transplantation because of their age.
This news about stem cell transplants comes as Robin Roberts returns as a host of Good Morning America tomorrow, five months after her successful transplant for MDS, a pre-leukemia blood disease that affects healthy blood cell formation in the bone marrow. Although Roberts is younger, more than 80% of newly diagnosed MDS cases occur in people over the age of 60.
According to the research presented at the BMT Tandem Meetings, 56 patients age 70 or older, most of whom received transplants for acute leukemia or MDS, were identified for the study. After being treated with low doses of chemotherapy and radiation, the majority of the patients received a peripheral blood stem cell transplant from a matched unrelated donor, while the remainder of the group received a transplant from a matched related donor. Among the findings in 46 patients who experienced nadir (when blood cell counts are at their lowest):
- the median time for blood cell counts to return to normal was 13 days;
- one year after transplant, the incidence of chronic graft-versus-host disease, a common transplant complication, was 37%;
- the incidence of survival without disease progression one year after transplant was 42%;
- the incidence of overall survival one year after transplant was 55%;
- the cumulative incidence of relapse was 34%;
- at day 100, a critical time for stem cell transplants, the incidence of non-relapse mortality was only 3.6%; and
- the incidence of non-relapse mortality one year after transplant was only 5.5%.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV